Skip to main content
OpenTrials
Completed

NCT Number: NCT04989829

Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Subjects

This is a one-arm, fixed-sequence study to compare the pharmacokinetic profiles of SHR6390 in absence and presence of prior administration of proton pump inhibitor Omeprazole. The increased gastric pH achieved by the treatment with multiple doses of Omeprazole might affect the absorption process of SHR6390.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Shanghai Xuhui Central Hospital

Shanghai, Shanghai Municipality, 200031, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sign the informed consent before the trial, and fully understand the trial content, process and possible adverse reactions;
  • Ability to complete the study as required by the protocol;
  • Healthy male or female subjects aged 18 to 45 (including 18 and 45) at the date of signing the informed consent;
  • Subjects shall ake effective contraceptive measures voluntarily within 7 months from the date of signing the informed consent form to the date of the last medication. Serum HCG test of fertile women before the study must be negative;
  • Male body weight ≥ 50 kg, female body weight ≥ 45 kg, and body mass index (BMI) within the range of 19 ~ 26 kg /m2 (including 19 and 26);
  • Healthy subjects identified by a detailed medical history;
  • Full physical examinations, including blood pressure and pulse rate measurement, 12-lead ECG or clinical laboratory test, are normal or abnormal but have no clinical significance.

Exclusion criteria

  • Blood donation or loss≥400 mL within 3 months prior to screening, or blood donation or loss≥200 mL, or blood transfusion within 1 months before screening;
  • Participating in any clinical trial or taking drugs that might damage organs within 3 months before screening;
  • Surgeries in the previous 6 months before screening;
  • Use of vaccines or biologicals within 2 weeks prior to screening;
  • Allergic constitution;
  • History of drug abuse or alcoholism, or positive for nicotine, alcohol and drug tests;
  • History of myocarditis, coronary heart disease, arrhythmia, stroke and so on, or 12 lead ECG demonstrating a corrected QT by Fridericia (QTcF) interval ≥450 msec;
  • With dysphagia or history of gut disease or surgery (gastrectomy, enterectomy, sleeve gastrectomy, etc) possibly affecting drug absorption;
  • Uncontrolled gut disease, such as peptic ulcer, colitis, pancreatitis, etc;
  • History of chronic kidney disease, renal insufficiency, anemia of renal failure, or creatinine clearance rate (CLCr) < 80 mL/min, or serum creatinine ≥ ULN.

Treatment and study plan

SHR6390、Omeprazole

Drug

SHR6390 tablet single dose、Omeprazol single dose.

Primary outcomes

  1. Cmax

    Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose

    Maximum observed serum concentration (Cmax) for SHR6390 after Single dose.

  2. AUC0-t

    Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose

    Area under the plasma concentration versus time curve (AUC0-t) for SHR6390 after Single dose

  3. AUC0-∞

    Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose

    Area under the plasma concentration versus time curve (AUC0-∞) for SHR6390 after Single dose

Secondary outcomes

  1. Tmax

    Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose

    Time to maximum observed serum concentration (Tmax) for SHR6390 after Single dose

  2. T1/2

    Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose

    Time to elimination half-life (T1/2) for SHR6390 after Single dose.[Time Frame

  3. CL/F

    Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose

    Apparent oral clearance (CL/F) for SHR6390 after Single dose

  4. Vz/F

    Time frame: from Day1 to Day7after the first dose and from Day17 to Day23 after the second dose

    Apparent Volume of Distribution (Vz/F) SHR6390 after Single dose

  5. Number of subjects with adverse events and severity of adverse events

    Time frame: from Day1 to Day30 after the first dose

Sponsors and collaborators

Lead sponsor

Jiangsu HengRui Medicine Co., Ltd.

Industry

Registry information

Official study title

A Single-centre, One-arm, Open-label, Fixed-sequence Study to Evaluate the Effect of Omeprazole on the Pharmacokinetics of SHR6390 in Healthy Male and Female Subjects

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Aug 4, 2021
Registry last updated
Jun 8, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.